KYNTRA BIO INC (KYNB) Stock Price, Forecast & Analysis
NASDAQ:KYNB • US31572Q8814
KYNB Key Statistics, Chart & Performance
The current stock price of KYNB is 8.32 USD. In the past month the price decreased by -7.25%.
KYNB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KYNB.
KYNB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYNB. KYNB may be in some trouble as it scores bad on both profitability and health.
KYNB Financial Highlights
Over the last trailing twelve months KYNB reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 102.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2598.87% | ||
| ROA | 157.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KYNB Forecast & Estimates
8 analysts have analysed KYNB and the average price target is 43.86 USD. This implies a price increase of 427.16% is expected in the next year compared to the current price of 8.32.
For the next year, analysts expect an EPS growth of 60.86% and a revenue growth -96.2% for KYNB
KYNB Ownership
KYNB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KYNB
Company Profile
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
Company Info
KYNTRA BIO INC
350 Bay Street, Suite 100 #6009
San Francisco CALIFORNIA US
Employees: 225
Phone: 14159781200
KYNTRA BIO INC / KYNB FAQ
What does KYNB do?
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
What is the current price of KYNB stock?
The current stock price of KYNB is 8.32 USD. The price increased by 6.12% in the last trading session.
Does KYNTRA BIO INC pay dividends?
KYNB does not pay a dividend.
What is the ChartMill technical and fundamental rating of KYNB stock?
KYNB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for KYNB stock?
The Revenue of KYNTRA BIO INC (KYNB) is expected to decline by -96.2% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns KYNTRA BIO INC?
You can find the ownership structure of KYNTRA BIO INC (KYNB) on the Ownership tab.
What is the Short Interest ratio of KYNTRA BIO INC (KYNB) stock?
The outstanding short interest for KYNTRA BIO INC (KYNB) is 2.7% of its float.